CTI BioPharma Corp.Find Ratings Reports
CTI BIOPHARMA CORP's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. CTI BIOPHARMA CORP is extremely liquid. Currently, the Quick Ratio is 2.06 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 455.76% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY16||Q2 FY15|
|Net Sales ($mil)||7.36||1.1|
|Net Income ($mil)||-19.77||-32.6|
|Balance Sheet||Q2 FY16||Q2 FY15|
|Cash & Equiv. ($mil)||76.72||54.86|
|Total Assets ($mil)||97.63||73.46|
|Total Debt ($mil)||22.87||51.62|
|Profitability||Q2 FY16||Q2 FY15|
|Gross Profit Margin||-256.17||-2797.82|
|Return on Assets||-76.49||-133.62|
|Return on Equity||-185.64||0.0|
|Debt||Q2 FY16||Q2 FY15|
|Share Data||Q2 FY16||Q2 FY15|
|Shares outstanding (mil)||282.87||180.37|
|Div / share||0.0||0.0|
|Book value / share||0.15||-0.07|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||643871.0||1317099.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.70 indicates valuation on par with the S&P 500 average of 2.79 and a significant discount versus the industry average of 11.17. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the industry average, indicating a discount. After reviewing these and other key valuation criteria, CTI BIOPHARMA CORP proves to trade at a discount to investment alternatives within the industry.
|CTIC NM||Peers 34.27||CTIC NM||Peers 28.50|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CTIC's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CTIC's P/CF is negative making the measure meaningless.
|CTIC NM||Peers 40.16||CTIC NA||Peers 0.44|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CTIC's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CTIC 2.70||Peers 11.17||CTIC 35.60||Peers 2.62|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CTIC is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CTIC is expected to have an earnings growth rate that significantly exceeds its peers.
|CTIC 2.02||Peers 170.51||CTIC -8.23||Peers 481.80|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CTIC is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CTIC significantly trails its peers on the basis of sales growth